Cathy Eng, Vanderbilt University Medical Center

Cathy Eng: Creating a new standard of care with Checkmate 8HW

Cathy Eng, VICC Associate Director of Strategic Relations and Research Partnerships at Vanderbilt-Ingram Cancer Center, posted the following on X:

“Checkmate 8HW: Nivo +/- ipi in metastatic dMMR (MSI-H) with superior PFS vs. nivo alone (39.3M vs. NR, HR = 0.62, p-value = 0.0003), creating a NEW standard of care; RR = 71% vs. 58% (p = 0.0011). Med f/U ~4 years.”

Cathy Eng: Creating a new standard of care with Checkmate 8HW Cathy Eng: Creating a new standard of care with Checkmate 8HW

ASCOGI25 cancer CheckMate-8HW colorectal cancer Dr. Cathy Eng FDA Oncology Immune Checkpoint Inhibitors metastatic dMMR MSI-H OncoDaily Oncology